Last updated: February 23, 2026
What Is NDC 00536-1387?
NDC 00536-1387 corresponds to Methylphenidate Hydrochloride Extended-Release Tablets, 20 mg. This medication is frequently prescribed for ADHD and narcolepsy management.
Current Market Landscape
Production and Availability
- Manufacturers: Several producers, including Allergan (Teva), Mylan, and Sun Pharma, produce methylphenidate ER formulations.
- Market Size: The global ADHD drug market was valued at approximately USD 12 billion in 2021, with methylphenidate ER products comprising around 35% of that value ([1]).
Demand Dynamics
- Prevalence: ADHD diagnosis rates are rising. CDC reported an increase from 7.8% in 2003 to 9.4% in 2016 among children in the U.S.
- Insurance Coverage: Most methylphenidate prescriptions are covered by commercial insurance and Medicaid, affecting pricing and reimbursement.
Competition
- Multiple branded and generic methylphenidate ER formulations compete at the same dosage.
- Patent expirations for key products have increased generic competition, pressuring prices.
Pricing Overview
Historical Pricing Trends
| Year |
Average Wholesale Price (AWP) for 30 Tablets, 20 mg |
Estimated National Average Sale Price (ASP) |
| 2020 |
USD 150 |
USD 135 |
| 2021 |
USD 140 |
USD 125 |
| 2022 |
USD 125 |
USD 110 |
Prices for NDC 00536-1387 specifically tend to align with the average generic methylphenidate ER 20 mg prices, though discounts and rebates influence actual transaction prices.
Market Price Projections (Next 3 Years)
- Prices are projected to decline at an average rate of 5-8% annually due to intensified generic competition.
- By 2025, average ASPs are expected around USD 90-100 for 30 tablets.
Factors Affecting Future Pricing
- Patent Litigation and Exclusivity: Patent litigations or extensions can temporarily stabilize or inflate prices.
- Regulatory Changes: Policy shifts toward biosimilars or generics could further reduce prices.
- Demand Fluctuations: Increased acceptance of generic alternatives and overprescription risks could influence demand and price.
Regulatory and Policy Environment
- The FDA approved multiple generics for methylphenidate ER formulations, facilitating price reductions.
- Medicaid and Medicare Part D reimbursement policies influence net price and access.
Market Entry and Innovation Outlook
- Generic manufacturers are expanding their production capacity.
- Reformulations focusing on abuse-deterrent features are under development but have limited impact on NDC 00536-1387, which is standard ER.
Summary of Price Drivers
- Increased Competition: Drives down prices.
- Reimbursement Policies: Affect net prices; more restrictive formularies pressure prices downward.
- Demand Trends: Rising ADHD diagnosis supports volume, but price discounts persist due to competition.
- Patent Status: Expiry of active patents enhances generic market penetration and price erosion.
Key Takeaways
- NDC 00536-1387, a methylphenidate ER product, is part of a highly competitive segment.
- Prices have declined over recent years, with further reductions anticipated.
- Market prices are sensitive to policy, patent, and demand factors.
- The generic landscape will continue to pressure prices through 2025.
- Manufacturers and investors should monitor patent statuses and regulatory developments for pricing opportunities.
FAQs
Q1: How does patent expiry affect methylphenidate ER prices?
A: Patent expiry allows generic manufacturers to enter the market, increasing competition and typically lowering prices.
Q2: What are the main factors influencing future methylphenidate ER prices?
A: Competition, regulatory policies, demand for ADHD medications, and patent statuses.
Q3: Is there potential for price stabilization?
A: Only temporarily, usually around patent litigations or supply constraints; general trend favors price decline.
Q4: How does Medicaid coverage impact pricing?
A: Medicaid often negotiates lower prices, reducing the net cost to payers and influencing market rates.
Q5: Are branded versions likely to maintain higher prices?
A: Due to patent protections, branded versions can command higher prices, but these protections are finite.
References
[1] Grand View Research. (2022). Methylphenidate market analysis. https://www.grandviewresearch.com/industry-analysis/adhd-drugs-market
